ABVX

Abivax S.A. Q1 2025 Financial Summary (Form 6-K)

Business Context and Reporting Period

Abivax S.A., a clinical-stage biotechnology company, reported unaudited interim condensed consolidated financial results for the three months ended March 31, 2025. The company focuses on developing therapeutics for chronic inflammatory diseases, primarily its lead candidate obefazimod. Key milestones include the full enrollment of Phase 3 ABTECT trials for ulcerative colitis (UC) in April 2025 and ongoing Phase 2b trials for Crohn's disease (CD). The financial statements are prepared in accordance with IFRS and presented in euros.

Key Financial Metrics

Debt and Liquidity: As of March 31, 2025, total financial debt obligations were €109.4 million. The company holds €103.6 million in cash and cash equivalents. Management expects to fund operations through the fourth quarter of 2025 based on current cash and expected Research Tax Credit (CIR) reimbursements.

Material Changes vs. Prior Period

• Net Loss Increase: Net loss increased by 22% (€9.5 million) to €52.4 million, driven by higher R&D spend and a shift from net financial income to net financial loss.
• R&D Expenses: Increased by 10% (€3.6 million) to €39.3 million. This was primarily due to a €3.0 million increase in Crohn's disease program costs and €2.7 million in transversal activities (headcount expansion and equity awards), partially offset by a €1.3 million decrease in UC program costs.
• Sales & Marketing: Decreased by 57% (€1.1 million) to €0.9 million due to the reduction of non-critical expenses to manage cash burn.
• Financial Results: The company reported a net financial loss of €5.2 million compared to net financial income of €1.8 million in Q1 2024. This reversal was driven by interest expenses on senior secured convertible bonds and foreign exchange losses, offset by lower interest income.
• Equity Position: Shareholders' equity turned negative to -€6.6 million due to accumulated losses.

Outlook, Risks, and Management Commentary

• Going Concern: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern for a period of 12 months from the date of issuance. Additional financing (equity, debt, or out-licensing) will be required beyond Q4 2025.
• Clinical Outlook: Top-line results for the Phase 3 ABTECT UC induction trials are expected in Q3 2025. The company expects to announce a follow-on candidate selection in H2 2025.
• Financing Strategy: The company has an At-The-Market (ATM) program allowing for up to $150 million in sales of ADSs, though no shares have been sold as of March 31, 2025. A shelf registration (Form F-3) covers up to $350 million.
• Risks: Key risks include the uncertainty of clinical trial outcomes, the need for substantial additional capital, and potential impacts from geopolitical conflicts (e.g., Russia-Ukraine) on clinical sites and supply chains.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the €103.6 million cash balance to fund operations through Q4 2025, considering the high burn rate and negative equity position.
• Financing Needs: Assess the likelihood and terms of securing additional capital before Q4 2025 to avoid liquidity crises.
• Clinical Milestones: Monitor the Q3 2025 top-line data readout for the ABTECT Phase 3 UC trials, which is critical for future valuation and funding.
• Debt Obligations: Review the maturity profile of the €109.4 million in financial debt, including the Kreos/Claret and Heights convertible notes.
• Going Concern Status: Confirm management's plans to mitigate the "substantial doubt" regarding the company's ability to continue as a going concern.